The FDA has given Augmenix 510(k) clearance to market TraceIT, an injectable synthetic hydrogel used to mark soft tissue radiographically before surgery. The technology, which can be viewed through MRI and other ultrasound modalities, is designed to help streamline image fusion and enhance soft-tissue alignment.
FDA clears absorbable soft-tissue marker from Augmenix
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||